Xilio Therapeutics (XLO) Other Operating Expenses (2020)

Xilio Therapeutics (XLO) reported Other Operating Expenses of $37.9 million for Q4 2020.

Xilio Therapeutics (XLO) Other Operating Expenses (2020) Analysis & Trends

Xilio Therapeutics (XLO) has 1 years of Other Operating Expenses data on file, last reported at $37.9 million in Q4 2020.

For the quarter ending Q4 2020, Other Operating Expenses changed N/A year-over-year to $37.9 million; the trailing twelve-month figure through Sep 2021 stood at $37.9 million (changed N/A YoY), and the FY2020 full-year result was $37.9 million, changed N/A from the prior year.
Other Operating Expenses held at $37.9 million in Q4 2020.
In the past five years, Other Operating Expenses ranged from a high of $37.9 million in Q4 2020 to a low of $37.9 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,102.16 Bn	67,101.87 Bn	-
2	Nanobiotix	1,909.44 Bn	1,909.38 Bn	-
3	Akari Therapeutics	989.71 Bn	989.71 Bn	-
4	BeOne Medicines	471.58 Bn	466.79 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.97 Bn	114.72 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.93 Bn	61.18 Bn	3.31 Bn
7	Belite Bio	62.68 Bn	62.68 Bn	-
8	Argenx Se	55.80 Bn	50.61 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.37 Bn	34.36 Bn	959.66 Mn
10	Xilio Therapeutics	144.68 Mn	-5.62 Mn	-

Download Data

Date	Value
Dec 31, 2020	37.91 Mn